Literature DB >> 21556640

Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas.

J Mattern1, R Koomagi, M Volm.   

Abstract

Vascular endothelial growth factor (VEGF), a secreted endothelial-specific growth factor, and microvessel density was examined in 204 primary non-small cell lung carcinomas. The expression of VEGF was evaluated by immunohistochemical staining using an anti-VEGF antibody. Positive staining was obtained in 125 out of 204 cases (61%). Tumor vascularity was quantitatively assessed by microvessel counting after staining with the endothelial-specific marker factor VIII. The mean microvessel count for all patients was 9.6+/-10.4. Expression of VEGF was closely associated with increment of microvessel density. Postoperative follow-up of patients demonstrated a trend that survival time of patients with VEGF-positive tumors was worse than that of patients with VEGF-negative tumors. In contrast, microvessel density was not a prognostic factor.

Entities:  

Year:  1995        PMID: 21556640     DOI: 10.3892/ijo.6.5.1059

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects.

Authors:  F Fraioli; M Anzidei; G Serra; S Liberali; A Fiorelli; F Zaccagna; F Longo; M Anile; C Catalano
Journal:  Br J Radiol       Date:  2013-08-01       Impact factor: 3.039

Review 2.  Angiogenesis in epithelian ovarian cancer.

Authors:  E S Bamberger; C W Perrett
Journal:  Mol Pathol       Date:  2002-12

Review 3.  Bevacizumab in non-small cell lung cancer.

Authors:  Francesco Di Costanzo; Francesca Mazzoni; Marinella Micol Mela; Lorenzo Antonuzzo; Daniele Checcacci; Matilde Saggese; Federica Di Costanzo
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.

Authors:  Anil Potti; Apar Kishor Ganti; Ketki Tendulkar; Kaley Sholes; Sidharth Chitajallu; Michael Koch; Steven Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-05       Impact factor: 4.553

5.  Ets-1 gene expression in patients with thymoma.

Authors:  Hidefumi Sasaki; Yoshihiro Kobayashi; Masayuki Tanahashi; Haruhiro Yukiue; Motoki Yano; Masahiro Kaji; Masanobu Kiriyama; Ichiro Fukai; Yosuke Yamakawa; Yoshitaka Fujii
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-12

6.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

7.  A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.

Authors:  G Fontanini; P Faviana; M Lucchi; L Boldrini; A Mussi; T Camacci; M A Mariani; C A Angeletti; F Basolo; R Pingitore
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

8.  Microvascular proliferation is associated with aggressive tumour features and reduced survival in lung adenocarcinoma.

Authors:  Maria Ramnefjell; Christina Aamelfot; Sura Aziz; Lars Helgeland; Lars A Akslen
Journal:  J Pathol Clin Res       Date:  2017-09-12

9.  Flattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer.

Authors:  Luo Fang; Ying He; Yinghui Tong; Luying Hu; Wenxiu Xin; Yujia Liu; Like Zhong; Yiwen Zhang; Ping Huang
Journal:  Oncotarget       Date:  2017-05-02

10.  The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  A-P Meert; M Paesmans; B Martin; P Delmotte; T Berghmans; J-M Verdebout; J-J Lafitte; C Mascaux; J-P Sculier
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.